bullish
China Retail Pharmacy Industry - New Game Rule, New Challenges, New Outlook
Xinyao has highlighted this Insight as a Top Pick
290 Views27 Apr 2023 08:55
China's retail pharmacy market has entered a new era with new game rule.As industry growth is slowing down, which companies are the first to establish new omni-channel retail scenarios would stand out
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 6-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
- Viva Biotech Holdings (1873.HK) - The Restructuring Plan Would Not Turn Things Around20 Jun 2023
- Pre-IPO Laekna (PHIP Updates) - Some Key Points Worth the Attention14 Jun 2023
- China Resources Pharmaceutical (3320.HK) - Growth Recovery and SOE Advantages Improve the Outlook12 Jun 2023
- Ping An Healthcare and Technology Company Limited (1833.HK)- To Turn Things Around or to Fail Again?15 Mar 2023
- JD Health (6618.HK) - It's Time to Reassess the Business Prospects and Valuation09 Mar 2023
- Reform in China's Medical Service Industry: SOE-Run Hospitals Usher in a Critical Turning Point14 Feb 2023
x